托法替布与TNF抑制剂治疗类风湿关节炎的恶性肿瘤风险:开放标签随机对照ORAL Surveillance试验结果
ORAL Surveillance开放标签随机对照试验纳入4362例≥50岁且≥1项心血管危险因素的类风湿关节炎患者,比较托法替布5 mg或10 mg每日两次与TNF抑制剂。托法替布组排除NMSC的恶性肿瘤及NMSC发生率均高于TNFi,10 mg每日两次组肺癌风险高于TNFi;合并托法替布剂量组排除NMSC的恶性肿瘤风险在18个月前与TNFi相似(HR 0.93),18个月后分歧(HR 1.93)。
要点
- 托法替布(合并及单剂量)排除NMSC的恶性肿瘤和NMSC发生率高于TNFi。
- 托法替布10 mg每日两次的肺癌风险高于TNFi,肺癌为托法替布最常见亚型。
- 合并托法替布剂量排除NMSC的恶性肿瘤HR:基线至18个月0.93,18个月后1.93,交互p=0.0469。
核心结论
- 托法替布较TNFi增加恶性肿瘤风险,且风险在有大动脉粥样硬化性心血管疾病史或心血管风险评分升高的患者中最高。
- 作者认为这可能源于心血管风险与癌症的共同危险因素。
研究设计与样本
- 开放标签随机对照试验ORAL Surveillance(NCT02092467),纳入4362例≥50岁且≥1项额外心血管危险因素的类风湿关节炎患者。
- 患者接受托法替布5 mg(N=1455)或10 mg(N=1456)每日两次,或TNFi(N=1451)。
主要发现
- 托法替布(合并及单剂量)排除NMSC的恶性肿瘤及NMSC发生率均高于TNFi。
- 托法替布10 mg每日两次的肺癌风险高于TNFi,肺癌为托法替布治疗中最常见的恶性肿瘤亚型。
- 总体人群中,两种托法替布剂量与TNFi排除NMSC的恶性肿瘤风险在18个月前相似,18个月后分歧:合并托法替布剂量HR 0.93(95%CI 0.53至1.62,基线至18个月)vs HR 1.93(95%CI 1.22至3.06,18个月后),交互p=0.0469。
- Cox分析在各治疗组中识别出排除NMSC的恶性肿瘤、肺癌和NMSC的基线危险因素;交互分析一般未显示治疗组与危险因素之间存在统计学交互证据。
- 有大动脉粥样硬化性心血管疾病史或心血管风险评分升高与各治疗组更高的恶性肿瘤发生率相关。
关键数值与推荐
- 排除NMSC的恶性肿瘤:托法替布(合并及单剂量)发生率高于TNFi。
- NMSC:托法替布(合并及单剂量)发生率高于TNFi。
- 肺癌:托法替布10 mg每日两次风险高于TNFi。
- 合并托法替布剂量排除NMSC的恶性肿瘤HR:基线至18个月0.93(95%CI 0.53至1.62),18个月后1.93(95%CI 1.22至3.06),交互p=0.0469。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). METHODS: In an open-label, randomised controlled trial (ORAL Surveillance; NCT02092467), 4362 patients with RA aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 (N=1455) or 10 mg two times per day (N=1456) or TNFi (N=1451). Incidence rates (IRs; patients with first events/100 patient-years) and HRs were calculated for adjudicated malignancies excluding non-melanoma skin cancer (NMSC), NMSC and subtypes. Post hoc analyses for malignancies excluding NMSC, lung cancer and NMSC included risk factors identified via simple/multivariable Cox models and IRs/HRs categorised by baseline risk factors, history of atherosclerotic cardiovascular disease (HxASCVD) and cardiovascular risk scores. RESULTS: IRs for malignancies excluding NMSC and NMSC were higher with tofacitinib (combined and individual doses) versus TNFi. Risk of lung cancer (most common subtype with tofacitinib) was higher with tofacitinib 10 mg two times per day versus TNFi. In the overall study population, the risk of malignancies excluding NMSC was similar between both tofacitinib doses and TNFi until month 18 and diverged from month 18 onwards (HR (95% CIs) for combined tofacitinib doses: 0.93 (0.53 to 1.62) from baseline to month 18 vs 1.93 (1.22 to 3.06) from month 18 onwards, interaction p=0.0469). Cox analyses identified baseline risk factors across treatment groups for malignancies excluding NMSC, lung cancer and NMSC; interaction analyses generally did not show statistical evidence of interaction between treatment groups and risk factors. HxASCVD or increasing cardiovascular risk scores were associated with higher malignancy IRs across treatments. CONCLUSIONS: Risk of malignancies was increased with tofacitinib versus TNFi, and incidence was highest in patients with HxASCVD or increasing cardiovascular risk. This may be due to shared risk factors for cardiovascular risk and cancer. TRIAL REGISTRATION NUMBERS: NCT02092467, NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661.
引用
- Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022. PMID: 36600185. doi:10.1136/ard-2022-222543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。